Table 4. Characteristics at baseline for 1024 patients with EC stratified by age.
| Characteristic |
All patients
1024(%) |
Age groups (years) | P | ||||
| ≤50 | 51-65 | 66-70 | >70 | ||||
| 227(%) | 675(%) | 65(%) | 57(%) | ||||
| Completely surgically staged | 681(66.5%) | 156(68.7%) | 464(68.8%) | 37(57.1%) | 24(42.1%) | 0.001 | |
| Endometrioid carcinoma | 966(94.3%) | 218(96.0%) | 635(94.1%) | 58(89.2%) | 55(96.5%) | 0.173 | |
| Grade | G1 | 334(32.6%) | 85(37.4%) | 219(32.4%) | 17(26.2%) | 13(22.8%) | 0.230 |
| G2 | 444(43.4%) | 96(42.3%) | 293(43.4%) | 28(43.1%) | 27(47.4%) | ||
| G3 | 246(24.58%) | 46(20.3%) | 163(24.1%) | 20(30.8%) | 17(29.8%) | ||
| MI≥1/2 | 491(47.9%) | 71(31.3%) | 345(51.1%) | 40(61.5%) | 35(61.4%) | 0 | |
| LVSI+ | 157(15.3%) | 29(12.8%) | 110(16.3%) | 11(16.9%) | 7(12.3%) | 0.539 | |
| LUSI+ | 293(28.6%) | 94(41.4%) | 175(25.9%) | 9(13.8%) | 15(26.3%) | 0 | |
| CSI+ | 130(12.7%) | 47(20.7%) | 70(10.4%) | 8(12.3%) | 5(8.8%) | 0.001 | |
| FIGO 2009 stage | Ia | 474(46.3%) | 129(56.8%) | 302(44.7%) | 22(33.8%) | 21(36.8%) | 0 |
| Ib | 421(41.1%) | 51(22.5%) | 304(45.0%) | 35(53.8%) | 31(54.4%) | ||
| II | 129(12.6%) | 47(20.7%) | 69(10.2%) | 8(12.3%) | 5(8.8%) | ||
| ESMO-ESGO-ESTRO Risk classification | Low risk | 291(28.4%) | 90(39.6%) | 174(25.8%) | 11(16.9%) | 16(28.1%) | 0 |
| Intermediate risk | 298(29.1%) | 40(17.6%) | 217(32.1%) | 21(32.3%) | 20(35.1%) | ||
| High-intermediate risk | 180(17.6%) | 34(15.0%) | 125(18.5%) | 15(23.1%) | 6(10.5%) | ||
| High risk | 255(24.9%) | 63(27.8%) | 159(23.6%) | 18(27.7%) | 15(26.3%) | ||
| VRT alone | 475(46.4%) | 102(44.9%) | 313(46.4%) | 27(41.5%) | 33(57.9%) | 0.279 | |
| Chemotherapy | 211(20.6%) | 50(22.0%) | 143(21.2%) | 14(21.5%) | 4(7.0%) | 0.035 | |
| Late rectal toxicity Grade≥2 | 40(3.9%) | 6(2.6%) | 25(3.7%) | 3(5.4%) | 6(10.4%) | 0.08 | |
| Late urinary toxicity Grade≥2 | 7(0.7%) | 0 | 6(0.8%) | 1(1.8%) | 0 | 0.399 | |
| Late hematologic toxicity Grade≥2 | 13(1.3%) | 2(1.0%) | 10(1.5%) | 0 | 1(2.1%) | 0.741 | |
| Cancer-specific mortality | 38(3.7%) | 4(1.8%) | 20(3.0%) | 5(7.7%) | 9(15.8%) | 0 | |